Wall Street analysts forecast that Abbott Laboratories (NYSE:ABT) will post earnings of $0.73 per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have made estimates for Abbott Laboratories’ earnings, with the lowest EPS estimate coming in at $0.72 and the highest estimate coming in at $0.74. Abbott Laboratories posted earnings of $0.65 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 12.3%. The firm is expected to announce its next quarterly earnings results on Wednesday, January 24th.

On average, analysts expect that Abbott Laboratories will report full-year earnings of $2.49 per share for the current fiscal year, with EPS estimates ranging from $2.47 to $2.50. For the next financial year, analysts forecast that the firm will post earnings of $2.83 per share, with EPS estimates ranging from $2.80 to $2.85. Zacks’ EPS averages are an average based on a survey of analysts that that provide coverage for Abbott Laboratories.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.01. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The firm had revenue of $6.83 billion for the quarter, compared to analyst estimates of $6.72 billion. During the same quarter in the previous year, the company posted $0.59 EPS. The business’s revenue was up 28.8% on a year-over-year basis.

ABT has been the topic of a number of analyst reports. Cowen reiterated a “buy” rating on shares of Abbott Laboratories in a research report on Sunday, September 24th. Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research report on Friday, September 22nd. Bank of America reiterated a “buy” rating and issued a $60.00 price target (up previously from $56.00) on shares of Abbott Laboratories in a research report on Wednesday, October 4th. Royal Bank Of Canada reiterated a “buy” rating and issued a $55.00 price target on shares of Abbott Laboratories in a research report on Tuesday, October 3rd. Finally, Jefferies Group reiterated a “buy” rating and issued a $65.00 price target on shares of Abbott Laboratories in a research report on Thursday, October 19th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Abbott Laboratories currently has an average rating of “Buy” and a consensus target price of $56.81.

Abbott Laboratories (ABT) traded down $0.13 during midday trading on Friday, hitting $54.66. The company’s stock had a trading volume of 7,828,595 shares, compared to its average volume of 6,609,666. Abbott Laboratories has a 1 year low of $37.42 and a 1 year high of $56.69. The company has a market cap of $95,228.27, a price-to-earnings ratio of 22.70, a PEG ratio of 2.05 and a beta of 1.06. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 15th. Investors of record on Friday, October 13th were given a dividend of $0.265 per share. The ex-dividend date of this dividend was Thursday, October 12th. This represents a $1.06 annualized dividend and a dividend yield of 1.94%. Abbott Laboratories’s payout ratio is 83.47%.

In related news, insider Jaime Contreras sold 52,700 shares of the company’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $51.97, for a total transaction of $2,738,819.00. Following the sale, the insider now owns 58,739 shares in the company, valued at approximately $3,052,665.83. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Daniel Gesua Sive Salvadori sold 62,460 shares of the company’s stock in a transaction that occurred on Tuesday, September 26th. The stock was sold at an average price of $52.95, for a total value of $3,307,257.00. Following the transaction, the insider now directly owns 113,426 shares in the company, valued at $6,005,906.70. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 311,127 shares of company stock worth $16,958,579. 0.76% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. Tributary Capital Management LLC acquired a new position in Abbott Laboratories during the 3rd quarter worth approximately $106,000. Heritage Trust Co raised its stake in shares of Abbott Laboratories by 10.1% in the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock worth $106,000 after purchasing an additional 200 shares during the last quarter. Winfield Associates Inc. raised its stake in shares of Abbott Laboratories by 3.9% in the second quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock worth $116,000 after purchasing an additional 89 shares during the last quarter. Thompson Davis & CO. Inc. raised its stake in shares of Abbott Laboratories by 17.7% in the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock worth $120,000 after purchasing an additional 370 shares during the last quarter. Finally, JFS Wealth Advisors LLC raised its stake in shares of Abbott Laboratories by 349.0% in the second quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock worth $131,000 after purchasing an additional 2,094 shares during the last quarter. 71.01% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/12/07/0-73-eps-expected-for-abbott-laboratories-abt-this-quarter.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Get a free copy of the Zacks research report on Abbott Laboratories (ABT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Stock Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related stocks with our FREE daily email newsletter.